Curated News
By: NewsRamp Editorial Staff
June 19, 2026

LakeShore Biopharma Shareholders Approve Merger, Paving Way for Privatization

Discuss on Substack Discuss on Telegram View History of this news story on GitHub
Original Source

TLDR

  • LakeShore Biopharma shareholders approved a merger, taking the company private and delisting shares, potentially increasing value for remaining investors.
  • The merger requires 92.3% shareholder vote approval; 86.2% voted yes, and closing conditions must still be satisfied or waived.
  • This merger may accelerate LakeShore's development of vaccines for rabies, hepatitis B, and influenza, improving global public health.
  • LakeShore Biopharma, formerly YS Biopharma, uses the proprietary PIKA platform to develop vaccines and cancer therapeutics.

Impact - Why it Matters

This news matters because it signals a strategic shift for LakeShore Biopharma, a key player in vaccine development. As a private company, it can pursue long-term R&D without quarterly earnings pressure, potentially accelerating breakthroughs in treatments for Rabies, Hepatitis B, and Influenza. For investors, the delisting means they must evaluate their positions, while patients may benefit from faster innovation. The merger also reflects broader trends in biotech, where smaller firms seek private capital to fund ambitious pipelines.

Summary

In a decisive move toward privatization, LakeShore Biopharma Co., Ltd (OTC: LSBCF, LSBWF) announced that its shareholders have overwhelmingly approved the merger agreement with Oceanpine Skyline Inc. and its subsidiary. At an extraordinary general meeting held today, approximately 86.2% of votes cast favored the proposal, which will see the company become a wholly owned subsidiary of Oceanpine Skyline Inc. and delist from public markets. The merger, originally announced in November 2025 and amended in April 2026, is now one step closer to completion, subject to customary closing conditions.

LakeShore Biopharma, formerly known as YS Biopharma, is a global biopharmaceutical company focused on developing vaccines and therapeutic biologics for infectious diseases and cancer. Its proprietary PIKA® immunomodulating technology platform targets Rabies, Hepatitis B, Influenza, and other viral infections. With operations in China, Singapore, and the Philippines, the company has a strong pipeline of preventive and therapeutic biologics. The merger will result in the company's shares and warrants ceasing to trade on the OTC Markets and deregistration under the Securities Exchange Act of 1934.

The approval by 92.3% of outstanding shares underscores strong shareholder support for the transaction. The company will work diligently with Oceanpine Skyline Inc. to satisfy remaining conditions and close the merger in due course. This move is expected to provide LakeShore Biopharma with greater strategic flexibility as a private entity, allowing it to focus on long-term growth without the pressures of public market reporting. For more details, visit the original release on NEWMEDIAWIRE or the company's investor relations page at https://investors.lakeshorebio.com/.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, LakeShore Biopharma Shareholders Approve Merger, Paving Way for Privatization

blockchain registration record for this content.